Rutika Mehta, MD, MPH

home / authors / rutika-mehta-md-mph

Articles

Dr. Mehta on Frontline and Adjuvant Treatments in ESCC

February 10th 2023

Rutika Mehta, MD, MPH, discusses which patients with esophageal squamous cell carcinoma may benefit most from the different frontline treatment options available and highlights key treatment developments with adjuvant immunotherapy plus chemotherapy.

Dr. Mehta on TAS-102/Ramucirumab Combo Trial in Gastric/GEJ Cancer

Rutika Mehta, MD, MPH

October 2nd 2019

Rutika Mehta, MD, MPH, discusses a phase II trial that will combine ramucirumab with TAS-102 in patients with advanced gastric and gastroesophageal junction cancer.

Dr. Mehta on Recent Progress Made in Advanced Gastric Cancer

Rutika Mehta, MD, MPH

September 24th 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist, Moffitt Cancer Center, discusses recent progress that has been made in advanced gastric cancer.

Dr. Mehta on Rationale for a Phase II Trial of TAS-102/Ramucirumab in Gastric/GEJ Cancer

Rutika Mehta, MD, MPH

June 19th 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist, Moffitt Cancer Center, discusses the rationale and design of a phase II study of TAS-102 (trifluridine/tipiracil; Lonsurf) in combination with ramucirumab (Cyramza) in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma (NCT03686488).

Dr. Mehta on Immunotherapy in Gastric/GEJ Cancer

Rutika Mehta, MD, MPH

March 22nd 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist at Moffitt Cancer Center, discusses the use of immunotherapy in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma.